LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

LLY

745.48

-1.34%↓

JNJ

153.61

+0.7%↑

UNH

321.58

+1.9%↑

ABBV

184.82

-0.47%↓

NVO

68.12

+1.76%↑

Search

Innoviva Inc

Closed

SectorHealthcare

18.78 1.08

Overview

Share price change

24h

Current

Min

18.55

Max

18.86

Key metrics

By Trading Economics

Income

-67M

-47M

Sales

-3.2M

89M

P/E

Sector Avg

51.694

56.602

EPS

0.26

Profit margin

-52.559

Employees

127

EBITDA

17M

36M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+195.22% upside

Dividends

By Dow Jones

Next Earnings

29 Jul 2025

Market Stats

By TradingEconomics

Market Cap

-8.2M

1.2B

Previous open

17.7

Previous close

18.78

News Sentiment

By Acuity

63%

37%

343 / 382 Healthcare

Technical Score

By Trading Central

Confidence

Strong Bullish Evidence

Innoviva Inc Chart

Past performance is not a reliable indicator of future results.

Related News

20 May 2025, 20:54 UTC

Acquisitions, Mergers, Takeovers

PNC to Buy Private-Equity Agent Aqueduct Capital

20 May 2025, 20:50 UTC

Earnings

Palo Alto Networks Posts Higher 3Q Sales, Profit Slips

20 May 2025, 23:48 UTC

Acquisitions, Mergers, Takeovers

Kraft Heinz Evaluating Strategic Transactions, Berkshire Hathaway Steps Away From Board -- Update

20 May 2025, 23:42 UTC

Market Talk

Nikkei May Trade Rangebound Amid Tariff Uncertainty -- Market Talk

20 May 2025, 23:39 UTC

Market Talk

Gold Steady, Supported by Lingering U.S. Fiscal-Deficit Concerns -- Market Talk

20 May 2025, 23:08 UTC

Market Talk

James Hardie's Repair & Remodel Outlook Surprises RBC -- Market Talk

20 May 2025, 22:46 UTC

Acquisitions, Mergers, Takeovers

Gold Road: Takeover Remains Subject to Independent Expert Findings; Shareholder, Court Approval

20 May 2025, 22:45 UTC

Acquisitions, Mergers, Takeovers

Gold Road: Notified Australia Government Has No Objections to Takeover by Gold Fields

20 May 2025, 22:20 UTC

Top News

In Latest EV Pullback, Ford to Share Battery Plant With Nissan -- WSJ

20 May 2025, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Adj EPS 37c >ZTO

20 May 2025, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q EPS 34c >ZTO

20 May 2025, 22:00 UTC

Earnings

ZTO Express (Cayman) 1Q Rev $1.5B >ZTO

20 May 2025, 21:44 UTC

Earnings

James Hardie Industries 4Q Adj EPS 36c >JHX

20 May 2025, 21:44 UTC

Earnings

James Hardie Industries: Sees FY26 North America Net Sales Growth Up Low Single Digits >JHX

20 May 2025, 21:44 UTC

Earnings

James Hardie Industries 4Q EPS 10c >JHX

20 May 2025, 21:44 UTC

Earnings

James Hardie Industries 4Q Sales $972M >JHX

20 May 2025, 20:52 UTC

Top News

Elon Musk to Cut Back Political Spending -- 3rd Update

20 May 2025, 20:52 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

20 May 2025, 20:52 UTC

Market Talk

Mexican Stocks Near Record High As Trade Concerns Ease -- Market Talk

20 May 2025, 20:30 UTC

Acquisitions, Mergers, Takeovers

PNC Financial: Aqueduct Acquisition Expected to Close in Mid-Summer, Terms Won't be Disclosed >PNC

20 May 2025, 20:28 UTC

Acquisitions, Mergers, Takeovers

PNC Bank Agrees To Acquire Aqueduct Capital Group To Complement Harris Williams Capabilities >PNC

20 May 2025, 20:23 UTC

Acquisitions, Mergers, Takeovers

Tesla CEO Musk Says He Plans to Be at White House for a Couple Days Every Few Weeks

20 May 2025, 20:22 UTC

Earnings

XP 1Q Adj EPS BRL2.29 >XP

20 May 2025, 20:22 UTC

Earnings

XP 1Q Rev BRL4.345B >XP

20 May 2025, 20:21 UTC

Acquisitions, Mergers, Takeovers

Tesla CEO Musk: 'We're in the Big Bang of Intelligence Explosion'

20 May 2025, 20:20 UTC

Top News

Fed's Bostic Signals Longer Delay in Cutting Interest Rates -- Barrons.com

20 May 2025, 20:19 UTC

Acquisitions, Mergers, Takeovers

Tesla CEO Musk Says He Doesn't Currently Have Plans to Merge Tesla, xAI

20 May 2025, 20:11 UTC

Top News

Venezuela Frees U.S. Air Force Veteran in Overture to Trump -- Update

20 May 2025, 20:09 UTC

Earnings

Palo Alto Networks 3Q Remaining Performance Obligation $13.5 B >PANW

20 May 2025, 20:08 UTC

Earnings

Palo Alto Networks Sees FY25 Adj EPS $3.26-Adj EPS $3.28 >PANW

Peer Comparison

Price change

Innoviva Inc Forecast

Price Target

By TipRanks

195.22% upside

12 Months Forecast

Average 55 USD  195.22%

High 55 USD

Low 55 USD

Based on 1 Wall Street analysts offering 12 month price targets forInnoviva Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

1 ratings

1

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

18.57 / 18.75Support & Resistance

Short Term

Strong Bullish Evidence

Intermediate Term

Weak Bullish Evidence

Long Term

Neutral Evidence

Sentiment

By Acuity

343 / 382 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Above average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.